AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15696983 — intervention group
Group type: COMPARATOR
Intervention: IPL
Number of subjects: 10
Study 12592236 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate/ethinyl estradiol combinations (0/5, 0.25/5, 1/5, 0/10, 0.5/10, or 1/10)
Number of subjects: 945
Study 12592236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/5 norethindrone acetate/ethinyl estradiol
Number of subjects: 945
Study 12592236 — intervention group
Group type: EXPERIMENTAL
Intervention: Other norethindrone acetate/ethinyl estradiol combinations
Number of subjects: 945
Study 12592236 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogens/2.5 mg medroxyprogesterone acetate
Number of subjects: 945
Study 10319056 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms b.i.d.
Number of subjects: 165
Study 10319056 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 micrograms q.i.d.
Number of subjects: 165
Study 10319056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 8568002 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin puncture blood
Number of subjects: 32
Study 8568002 — intervention group
Group type: COMPARATOR
Intervention: Venous blood
Number of subjects: 32
Study 2569996 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine administered three times daily
Number of subjects: 21
Study 2569996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydroxyzine administered three times daily
Number of subjects: 21
Study 2569996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2569996 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 21
Study 383108 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg indoprofen
Number of subjects: 18
Study 383108 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg naproxen
Number of subjects: 18
Study 29926357 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal bupivacaine 0.5%
Number of subjects: 100
Study 29926357 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 27010144 — intervention group
Group type: EXPERIMENTAL
Intervention: Early blood purification therapy
Number of subjects: 32
Study 27010144 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 32
Study 25566930 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg (on-dialysis)
Number of subjects: 10
Study 25566930 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg (off-dialysis)
Number of subjects: 10
Study 25566930 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 10
Study 24384954 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral mini-incision total hip arthroplasty (Group A)
Number of subjects: 94
Study 24384954 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterolateral incision total hip arthroplasty (Group B)
Number of subjects: 94
Study 20199985 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract supplements (average of 82 mg/day for 6-12 months)
Number of subjects: 1240
Study 20199985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1240
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg salbutamol via pMDI+ Volumatic
Number of subjects: 18
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg salbutamol via pMDI+ Volumatic
Number of subjects: 18
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg salbutamol via Diskus
Number of subjects: 18
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg salbutamol via Diskus
Number of subjects: 18
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: Finney method
Number of subjects: 18
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: Emax method
Number of subjects: 18
Study 17997115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 18
Study 17997115 — intervention group
Group type: COMPARATOR
Intervention: pMDI+ Volumatic
Number of subjects: 18
Study 16203593 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG + ST (fetal ECG waveform analysis combined with cardiotocography)
Number of subjects: 4966
Study 16203593 — intervention group
Group type: COMPARATOR
Intervention: CTG only (control group)
Number of subjects: 4966
Study 12887140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine 150 mg/kg
Number of subjects: 0
Study 12887140 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/70 kg
Number of subjects: 0
Study 12887140 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 37.5 mg
Number of subjects: 0
Study 12887140 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine 20 mg
Number of subjects: 0
Study 12887140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10505460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 30
Study 10505460 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 8607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target prothrombin time ratio, 1.3 to 1.8; approximate international normalized ratio, 2.0 to 4.5)
Number of subjects: 1100
Study 8607726 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg daily, enteric coated)
Number of subjects: 1100
Study 8607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1100
Study 8607726 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1100
Study 8607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 75 years or younger receiving anticoagulation
Number of subjects: 1100
Study 8607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 75 years receiving anticoagulation
Number of subjects: 1100
Study 8607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 75 years or younger
Number of subjects: 1100
Study 8607726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients older than 75 years
Number of subjects: 1100
Study 2019027 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirmenol
Number of subjects: 18
Study 2019027 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 18
Study 6101151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide oral solution (500 mg)
Number of subjects: 6
Study 6101151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide tablets (500 mg)
Number of subjects: 6
Study 31149737 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 5.0 CAHPS survey
Number of subjects: 3720
Study 31149737 — intervention group
Group type: COMPARATOR
Intervention: Version 4.0 CAHPS survey
Number of subjects: 3720
Study 28591763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 18 g
Number of subjects: 24
Study 28591763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 30 g
Number of subjects: 24
Study 28591763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 6 g
Number of subjects: 24
Study 28591763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 12 g
Number of subjects: 24
Study 28591763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 24 g
Number of subjects: 24
Study 28591763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 42 g
Number of subjects: 24
Study 28591763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26396030 — intervention group
Group type: EXPERIMENTAL
Intervention: Perihematomal edema (PHE) volume expansion in the first 72 hours (iPHE)
Number of subjects: 596
Study 26396030 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis for basal ganglia ICH and small (<30 mL) ICH
Number of subjects: 596
Study 26396030 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute increase in PHE during 72 hours
Number of subjects: 596
Study 23408163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication reviews
Number of subjects: 369
Study 23408163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist-led medication reviews)
Number of subjects: 369
Study 21251307 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 59
Study 21251307 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 59
Study 21251307 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 59
Study 19336424 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 60
Study 19336424 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 60
Study 17575493 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiofrequency (CRF) denervation (80 degrees C)
Number of subjects: 60
Study 17575493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) denervation (2 Hz)
Number of subjects: 60
Study 17575493 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic (Control group)
Number of subjects: 60
Study 15234143 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 76
Study 15234143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (250 mg)
Number of subjects: 76
Study 15234143 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical apraclonidine 1%
Number of subjects: 76
Study 15234143 — intervention group
Group type: COMPARATOR
Intervention: All treated (acetazolamide and apraclonidine) vs. nontreated
Number of subjects: 76
Study 10710072 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS) with placebo (3-5 ml of ethanolamine oleate per varix and placebo injection at 50 microg/h)
Number of subjects: 70
Study 10710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (EVS) with octreotide (50 microg/h continuously for 5 days)
Number of subjects: 70
Study 10710072 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS) with placebo
Number of subjects: 70
Study 10710072 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy (EVS) with octreotide
Number of subjects: 70
Study 9029451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling with the aerosol reduction device for 5 minutes
Number of subjects: 12
Study 9029451 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling without the aerosol reduction device for 5 minutes
Number of subjects: 12
Study 8458451 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg gestrinone two times per week for 6 months
Number of subjects: 20
Study 8458451 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg gestrinone two times per week for 6 months
Number of subjects: 20
Study 3753671 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 12
Study 3753671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with sucralfate
Number of subjects: 12
Study 29808523 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training (RAT) plus physical therapy
Number of subjects: 48
Study 29808523 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only (Control)
Number of subjects: 48
Study 25151920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy coronary CT angiography (DECT) with 35 mL iodinated contrast
Number of subjects: 102
Study 25151920 — intervention group
Group type: COMPARATOR
Intervention: Standard iodinated contrast volume coronary CT angiography (SCCTA) with 80 mL iodinated contrast
Number of subjects: 102
Study 25151920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy coronary CT angiography (DECT)
Number of subjects: 102
Study 25151920 — intervention group
Group type: COMPARATOR
Intervention: Standard iodinated contrast volume coronary CT angiography (SCCTA)
Number of subjects: 102
Study 22438429 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 186
Study 22438429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents (BMS)
Number of subjects: 186
Study 22438429 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal references
Number of subjects: 186
Study 22438429 — intervention group
Group type: COMPARATOR
Intervention: Attenuated plaque at baseline
Number of subjects: 186
Study 19422648 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity intervention
Number of subjects: 502
Study 19422648 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 502
Study 19422648 — intervention group
Group type: EXPERIMENTAL
Intervention: High FNE children
Number of subjects: 502
Study 19278087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic toothbrush (Sonicare FlexCare)
Number of subjects: 48
Study 19278087 — intervention group
Group type: COMPARATOR
Intervention: Rotation-oscillation toothbrush (Oral-B Triumph)
Number of subjects: 48
Study 15970946 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular strength training (group A) for 3 months
Number of subjects: 119
Study 15970946 — intervention group
Group type: COMPARATOR
Intervention: Non-strengthening exercises (group B) for 3 months
Number of subjects: 119
Study 15970946 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B at postoperative day 7
Number of subjects: 119
Study 15970946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intake
Number of subjects: 119
Study 12028504 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg day-1)
Number of subjects: 165
Study 12028504 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg day-1)
Number of subjects: 165
Study 12028504 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate
Number of subjects: 165
Study 12028504 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 165
Study 10225583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 32
Study 10225583 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 32
Study 10225583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 32
Study 9291741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% oxytetracycline eye drops combined with a specific health education programme
Number of subjects: 1810
Study 9291741 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme only
Number of subjects: 1810
Study 9291741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass treatment only
Number of subjects: 1810
Study 9291741 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control village)
Number of subjects: 1810
Study 2195516 — intervention group
Group type: EXPERIMENTAL
Intervention: TDX method of determination
Number of subjects: 8
Study 2195516 — intervention group
Group type: COMPARATOR
Intervention: EMIT method of determination
Number of subjects: 8
Study 2195516 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release preparations of theophylline
Number of subjects: 8
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg kg‐1
Number of subjects: 145
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.02 mg kg‐1
Number of subjects: 145
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1
Number of subjects: 145
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 145
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 145
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 145
Study 37862 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 145
Study 31518175 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 553
Study 31518175 — intervention group
Group type: COMPARATOR
Intervention: Routine Surveillance (RS)
Number of subjects: 553
Study 29978375 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU Cholecalciferol drops
Number of subjects: 40
Study 29978375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28120591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin (0.2 mg/kg daily for 3 days)
Number of subjects: 96
Study 28120591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10, 5, 5 mg/kg every 24 hours for 3 days)
Number of subjects: 96
Study 28120591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study 23471762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 0
Study 23471762 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 0
Study 23471762 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 22583636 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan
Number of subjects: 2577
Study 22583636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2577
Study 20061726 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lotion containing niacinamide, panthenol, and tocopheryl acetate applied daily for 10 weeks
Number of subjects: 246
Study 20061726 — intervention group
Group type: COMPARATOR
Intervention: Control lotion applied daily for 10 weeks
Number of subjects: 246
Study 16777318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 70
Study 16261463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (0.5, 1.0, and 1.5 MAC)
Number of subjects: 30
Study 16261463 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (0.5, 1.0, and 1.5 MAC)
Number of subjects: 30
Study 16261463 — intervention group
Group type: COMPARATOR
Intervention: Control (patients awake after surgery)
Number of subjects: 30
Study 11985406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber foods (4 servings/day) plus telephone-based support service
Number of subjects: 150
Study 11985406 — intervention group
Group type: COMPARATOR
Intervention: Usual care (handout describing NCEP Step-1 diet)
Number of subjects: 150
Study 11985406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 10321168 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoGraf/N alone or with autogenous bone and/or demineralized freeze-dried bone
Number of subjects: 113
Study 10321168 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoGraf/N with demineralized freeze-dried bone allograft
Number of subjects: 113
Study 10321168 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoGraf/N with intraoral autogenous bone
Number of subjects: 113
Study 10321168 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoGraf/N with expanded polytetrafluoroethylene membrane
Number of subjects: 113
Study 10321168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus elevation procedure
Number of subjects: 113
Study 7654805 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional extension exercises of the spine (group A)
Number of subjects: 33
Study 7654805 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension exercises and exercises to stretch and strengthen scapular musculature (group B)
Number of subjects: 33
Study 7654805 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 2576362 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride (2 mg o.d., loading dose = 2 b.i.d. over the first three days)
Number of subjects: 20
Study 2576362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2576362 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride
Number of subjects: 20
Study 788143 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal group A polysaccharide vaccine
Number of subjects: 100000
Study 788143 — intervention group
Group type: COMPARATOR
Intervention: Haemophilus influenzae type b polysaccharide vaccine
Number of subjects: 100000
Study 6259981 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic leukocyte transfusions
Number of subjects: 58
Study 6259981 — intervention group
Group type: COMPARATOR
Intervention: Control (no leukocyte transfusions or only therapeutic leukocyte transfusions)
Number of subjects: 58
Study 31702469 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian Randomization (MR) methods
Number of subjects: 0
Study 31702469 — intervention group
Group type: COMPARATOR
Intervention: Traditional epidemiological studies
Number of subjects: 0
Study 29617066 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d
Number of subjects: 37
Study 29617066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 26940369 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized touch screen decision aid (CDA; n=33)
Number of subjects: 61
Study 26940369 — intervention group
Group type: COMPARATOR
Intervention: Literacy appropriate print tool (PT; n=28)
Number of subjects: 61
Study 24500238 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard or high-dose infusions of normal saline
Number of subjects: 592
Study 24500238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 592
Study 24500238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hydration
Number of subjects: 592
Study 24500238 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hydration)
Number of subjects: 592
Study 23001778 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries
Number of subjects: 168
Study 23001778 — intervention group
Group type: COMPARATOR
Intervention: Ovulation induction with gonadotrophins (recombinant FSH)
Number of subjects: 168
Study 21054884 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised clinical management pathway (specialist starts clinical pathway within 2 weeks)
Number of subjects: 250
Study 21054884 — intervention group
Group type: COMPARATOR
Intervention: Usual care (existing care until review by specialist at 6 weeks)
Number of subjects: 250
Study 17308327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3)
Number of subjects: 9